A Cohort Establishment Study of Total Management of Ovarian Cancer

• Sponsor: Sichuan Cancer Hospital and Research Institute (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT06018935
• Collaborator: (none)
• Enrollment: 500
• Anticipated Duration (Months): 24

Study Details

Study Description

Brief Summary

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Condition or Disease	Intervention/Treatment	Phase
Tumor of Female Reproductive System; Ovarian Cancer	Other: No intervention

Detailed Description

1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer);

2. To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures;

3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed;

4. To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Study Design

• Study Type: Observational
• Anticipated Enrollment: 500 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)
• Anticipated Study Start Date: Sep 1, 2023
• Anticipated Primary Completion Date: Sep 1, 2025
• Anticipated Study Completion Date: Sep 1, 2025

Outcome Measures

Primary Outcome Measures

1. Progress Freesurvival (PFS) [Average six months after study completion.]

   The time from the start of treatment until the patient progresses further or dies.

2. Overall Survival (OS) [Average six months after study completion.]

   Measure the time from the start of treatment to the time of death.

Secondary Outcome Measures

1. Occurrence of adverse reactions [Average six months after study completion.]

   All adverse events were recorded.

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;

2. Can cooperate with later follow-up.

Exclusion Criteria:

1. Patients with other malignant tumors or previous history of other malignant tumors;

2. Have cognitive impairment.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Sichuan Cancer Hospital and Research Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Dengfeng Wang, Deputy chief, Sichuan Cancer Hospital and Research Institute
• ClinicalTrials.gov Identifier: NCT06018935
• Other Study ID Numbers: LCATM202304
• First Posted: Aug 31, 2023
• Last Update Posted: Aug 31, 2023
• Last Verified: Aug 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Dengfeng Wang, Deputy chief, Sichuan Cancer Hospital and Research Institute: Ovarian cancer; Cohort study; Whole-process management
• Additional relevant MeSH terms: Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Genital Neoplasms, Female

Study Results

No Results Posted as of Aug 31, 2023